Ipratropium albuterol brand name
Pro Research Analysisby 
Searched over 200M research papers
Ipratropium Albuterol Brand Name: Combivent
Introduction to Ipratropium and Albuterol Combination Therapy
Ipratropium and albuterol are two medications commonly used in combination to treat respiratory conditions such as chronic obstructive pulmonary disease (COPD). This combination leverages the bronchodilatory effects of both drugs to provide enhanced relief from symptoms.
Mechanism of Action
Albuterol works by stimulating beta-2 adrenergic receptors in the lungs. This activation leads to the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP), resulting in the relaxation of bronchial smooth muscle, relief from bronchospasms, and a reduction in the release of inflammatory cell mediators1.
Ipratropium, on the other hand, is a synthetic quaternary ammonium compound that acts as a competitive muscarinic acetylcholine (ACh) receptor antagonist. By inhibiting vagally mediated reflexes, ipratropium prevents the increase in intracellular cyclic guanosine monophosphate (cGMP), which is typically a result of ACh interacting with muscarinic receptors on bronchial smooth muscle1.
Clinical Efficacy and Safety
The combination of albuterol and ipratropium has been shown to provide better improvement in airflow compared to either component alone. This combination therapy simplifies treatment by reducing the number of separate inhalers needed, thereby improving patient compliance2.
Brand Name: Combivent
The combination of albuterol and ipratropium is marketed under the brand name Combivent. This formulation was approved over 15 years ago and has been a significant advancement in the treatment of COPD2. Combivent provides a convenient and effective option for patients, combining the benefits of both medications into a single inhaler.
Conclusion
Combivent, the brand name for the combination of albuterol and ipratropium, offers a potent and convenient treatment option for individuals suffering from COPD. By combining the bronchodilatory effects of both drugs, Combivent enhances airflow and simplifies therapy, leading to better patient outcomes and compliance1 2.
Sources and full results
Most relevant research papers on this topic
Ipratropium/Albuterol
Ipratropium/Albuterol is a bronchodilator that relaxes bronchial smooth muscle, relieves bronchospasms, and reduces inflammation.
Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease
Combination albuterol-ipratropium therapy was once an innovative treatment for COPD, but newer treatments have surpassed its advantages in improving airflow and simplifying therapy.
Systematic ReviewPharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD.
Ipratropium combined with albuterol significantly reduces COPD exacerbations and costs, making it a cost-effective treatment option for patients.
RCT
Large Human Trial
Highly CitedEffect of nebulized ipratropium on the hospitalization rates of children with asthma.
Ipratropium bromide combined with albuterol and corticosteroid therapy significantly decreases hospitalization rates in children with severe asthma exacerbations.
RCTLarge Human TrialHighly CitedA comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma.
Nebulized ipratropium bromide and albuterol showed no significant additive benefit in treating acute asthma in inner city patients.
RCTLarge Human TrialHighly CitedComparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study.
Ipratropium bromide has longer duration of action and may be effective when beta 2 agonists are not effective in treating chronic obstructive pulmonary disease.
RCTIn chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group.
A combination of ipratropium and albuterol, administered by metered-dose inhaler, is more effective than either agent alone in improving lung function in COPD patients.
Efficacy of adding nebulized ipratropium bromide to nebulized albuterol therapy in acute bronchiolitis.
Adding nebulized ipratropium bromide to nebulized albuterol in infants with acute bronchiolitis resulted in no additional benefit in decreasing respiratory rate, accessory muscle score, wheeze score, oxygen saturation, or hospitalization rate.
RCTHighly CitedThe combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD.
A combination of ipratropium bromide and albuterol sulfate is superior to individual agents in identifying pulmonary function reversibility in COPD patients.
RCTLarge Human TrialHighly CitedSuperiority of ipratropium plus albuterol over albuterol alone in the emergency department management of adult asthma: a randomized clinical trial.
Ipratropium combined with initial albuterol nebulization significantly improves airflow and reduces hospital admissions in adults with acute asthma.
RCT